|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NAA60 |
Gene summary for NAA60 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NAA60 | Gene ID | 79903 |
| Gene name | N-alpha-acetyltransferase 60, NatF catalytic subunit | |
| Gene Alias | HAT4 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006323 | UniProtAcc | Q9H7X0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79903 | NAA60 | LZE4T | Human | Esophagus | ESCC | 2.13e-11 | 2.28e-01 | 0.0811 |
| 79903 | NAA60 | LZE5T | Human | Esophagus | ESCC | 1.39e-02 | 1.52e-01 | 0.0514 |
| 79903 | NAA60 | LZE7T | Human | Esophagus | ESCC | 8.98e-12 | 6.54e-01 | 0.0667 |
| 79903 | NAA60 | LZE8T | Human | Esophagus | ESCC | 5.18e-11 | 2.87e-01 | 0.067 |
| 79903 | NAA60 | LZE20T | Human | Esophagus | ESCC | 2.08e-08 | 2.21e-01 | 0.0662 |
| 79903 | NAA60 | LZE22T | Human | Esophagus | ESCC | 9.86e-05 | 2.92e-01 | 0.068 |
| 79903 | NAA60 | LZE24T | Human | Esophagus | ESCC | 1.45e-21 | 5.28e-01 | 0.0596 |
| 79903 | NAA60 | LZE21T | Human | Esophagus | ESCC | 1.59e-09 | 3.79e-01 | 0.0655 |
| 79903 | NAA60 | LZE6T | Human | Esophagus | ESCC | 1.32e-04 | 1.18e-01 | 0.0845 |
| 79903 | NAA60 | P1T-E | Human | Esophagus | ESCC | 2.51e-15 | 5.43e-01 | 0.0875 |
| 79903 | NAA60 | P2T-E | Human | Esophagus | ESCC | 5.35e-33 | 6.89e-01 | 0.1177 |
| 79903 | NAA60 | P4T-E | Human | Esophagus | ESCC | 1.53e-22 | 3.67e-01 | 0.1323 |
| 79903 | NAA60 | P5T-E | Human | Esophagus | ESCC | 9.49e-22 | 2.29e-01 | 0.1327 |
| 79903 | NAA60 | P8T-E | Human | Esophagus | ESCC | 9.79e-28 | 4.73e-01 | 0.0889 |
| 79903 | NAA60 | P9T-E | Human | Esophagus | ESCC | 1.70e-14 | 2.74e-01 | 0.1131 |
| 79903 | NAA60 | P10T-E | Human | Esophagus | ESCC | 2.53e-14 | 2.74e-01 | 0.116 |
| 79903 | NAA60 | P11T-E | Human | Esophagus | ESCC | 1.69e-20 | 6.77e-01 | 0.1426 |
| 79903 | NAA60 | P12T-E | Human | Esophagus | ESCC | 4.41e-42 | 7.41e-01 | 0.1122 |
| 79903 | NAA60 | P15T-E | Human | Esophagus | ESCC | 1.34e-32 | 6.89e-01 | 0.1149 |
| 79903 | NAA60 | P16T-E | Human | Esophagus | ESCC | 5.91e-17 | 2.21e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001657015 | Esophagus | ESCC | histone modification | 323/8552 | 463/18723 | 2.61e-26 | 7.88e-24 | 323 |
| GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
| GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
| GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
| GO:001839313 | Esophagus | ESCC | internal peptidyl-lysine acetylation | 114/8552 | 158/18723 | 1.16e-11 | 4.24e-10 | 114 |
| GO:000647513 | Esophagus | ESCC | internal protein amino acid acetylation | 115/8552 | 160/18723 | 1.43e-11 | 5.08e-10 | 115 |
| GO:00165735 | Esophagus | ESCC | histone acetylation | 110/8552 | 152/18723 | 1.95e-11 | 6.81e-10 | 110 |
| GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
| GO:004396712 | Esophagus | ESCC | histone H4 acetylation | 53/8552 | 67/18723 | 2.11e-08 | 4.03e-07 | 53 |
| GO:000632517 | Esophagus | ESCC | chromatin organization | 240/8552 | 409/18723 | 6.52e-08 | 1.14e-06 | 240 |
| GO:00439662 | Esophagus | ESCC | histone H3 acetylation | 43/8552 | 61/18723 | 7.57e-05 | 5.67e-04 | 43 |
| GO:00182061 | Esophagus | ESCC | peptidyl-methionine modification | 12/8552 | 13/18723 | 6.18e-04 | 3.32e-03 | 12 |
| GO:0031365 | Esophagus | ESCC | N-terminal protein amino acid modification | 21/8552 | 30/18723 | 6.17e-03 | 2.27e-02 | 21 |
| GO:0006474 | Esophagus | ESCC | N-terminal protein amino acid acetylation | 13/8552 | 17/18723 | 1.00e-02 | 3.42e-02 | 13 |
| GO:001657021 | Liver | HCC | histone modification | 283/7958 | 463/18723 | 2.68e-16 | 2.33e-14 | 283 |
| GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
| GO:00064732 | Liver | HCC | protein acetylation | 135/7958 | 201/18723 | 1.20e-12 | 5.92e-11 | 135 |
| GO:00435432 | Liver | HCC | protein acylation | 157/7958 | 243/18723 | 2.40e-12 | 1.12e-10 | 157 |
| Page: 1 2 3 4 5 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NAA60 | SNV | Missense_Mutation | c.337N>C | p.Glu113Gln | p.E113Q | Q9H7X0 | protein_coding | tolerated(0.2) | benign(0.143) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NAA60 | SNV | Missense_Mutation | c.479N>A | p.Arg160Lys | p.R160K | Q9H7X0 | protein_coding | tolerated(0.18) | possibly_damaging(0.56) | TCGA-AR-A0TZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Doxorubicin | PD | |
| NAA60 | SNV | Missense_Mutation | novel | c.290N>G | p.Ser97Cys | p.S97C | Q9H7X0 | protein_coding | tolerated(0.11) | probably_damaging(0.935) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NAA60 | SNV | Missense_Mutation | c.502N>G | p.Leu168Val | p.L168V | Q9H7X0 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-EK-A2IP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NAA60 | SNV | Missense_Mutation | c.362N>T | p.Ser121Phe | p.S121F | Q9H7X0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NAA60 | SNV | Missense_Mutation | c.518N>G | p.Ser173Cys | p.S173C | Q9H7X0 | protein_coding | tolerated(0.15) | possibly_damaging(0.706) | TCGA-EK-A2R7-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NAA60 | SNV | Missense_Mutation | novel | c.177C>A | p.Phe59Leu | p.F59L | Q9H7X0 | protein_coding | tolerated(0.18) | benign(0.113) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| NAA60 | SNV | Missense_Mutation | rs779804473 | c.328N>A | p.Val110Ile | p.V110I | Q9H7X0 | protein_coding | deleterious(0.01) | probably_damaging(0.983) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NAA60 | SNV | Missense_Mutation | c.452N>G | p.Asn151Ser | p.N151S | Q9H7X0 | protein_coding | tolerated(0.49) | benign(0.007) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NAA60 | SNV | Missense_Mutation | c.568G>A | p.Gly190Ser | p.G190S | Q9H7X0 | protein_coding | deleterious(0.01) | possibly_damaging(0.858) | TCGA-AP-A0LG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |